近期,重组胶原蛋白赛道的“械三证”争夺进入白热化阶段。手握3张械三证的锦波生物凭借技术壁垒和专利护城河稳坐头把交椅,而巨子生物在经历成分争议和股价暴跌后,正试图通过“药械组合”这一差异化路径实现弯道超车。这场关乎行业话语权的博弈,不仅折射出重组胶原蛋白产业的技术迭代,更揭示出医美监管政策的细化趋势。械三证作为国家药监局对高风险医疗器械的严格准入证明,其含金量正在加速攀升。根据国家药监局数据,...
Source Link近期,重组胶原蛋白赛道的“械三证”争夺进入白热化阶段。手握3张械三证的锦波生物凭借技术壁垒和专利护城河稳坐头把交椅,而巨子生物在经历成分争议和股价暴跌后,正试图通过“药械组合”这一差异化路径实现弯道超车。这场关乎行业话语权的博弈,不仅折射出重组胶原蛋白产业的技术迭代,更揭示出医美监管政策的细化趋势。械三证作为国家药监局对高风险医疗器械的严格准入证明,其含金量正在加速攀升。根据国家药监局数据,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.